Sunday, 14 August 2022

 

 

LATEST NEWS Maharaja Trophy: Pavan Deshpande, bowlers seal thumping win for Mysuru Warriors against Bengaluru Blasters Woman gang-raped in Assam; 1 held Aparshakti Khurana turns serious, all set to play a Kashmiri terrorist PV Sindhu pulls out of World Championships due to stress fracture Three killed in bomb blast in Pakistan's Waziristan Minor abducted, raped in Delhi MS Dhoni changes his Instagram DP to Indian tricolour to mark 75 years of independence Shane Watson, Daniel Vettori replace Herschelle Gibbs, Sanath Jayasuriya in World Giant team Origin and Popularity of Patiala Peg MLA Madan Lal Bagga & DC take stock of Aam Aadmi Clinic to be inaugurated by Punjab CM on Aug 15 BJP intensified the campaign to hoist the Tringa from house to house in the phases of the city Uni: Ranjit Bawa Unveils Captivating Poster & Release Date Of New Single Track One MLA - One Pension' will save Rs 100 crore taxpayers money in 5 years : Malvinder Singh Kang Why Mindy Kaling says she could never write 'Euphoria' Bangladesh appoint Shakib Al Hasan as T20 captain until 2022 World Cup, name Asia Cup squad If there's no competition then nobody would want to improve themselves : Sudhanshu Pandey Pretoria Capitals sign SA pace duo Anrich Nortje, Migael Pretorius for CSA T20 League Simi Singh replaces Andy McBrine in Ireland's squad for last two T20I against Afghanistan Idris Elba shares moment when a bat interrupted steamy shower with wife Raju Srivastava's family says his condition is stable Deputy Commissioner Surabhi Malik inspects full dress rehearsal of 75th state level Independence Day Function

 

Antibody therapy less effective against new Omicron strains : Lancet

Omicron Variant, Delta Plus Covid variant, Delta Covid-19 variant, Coronavirus, Health, Research, Study, Researchers, COVID 19, Novel Coronavirus, Fight Against Corona, Covaxin, Covishield, Oxygen, SARS-CoV-2, Sputnik V, Oxygen Plants, Pfizer, Astra Zeneca, Oxygen Concentrator, Remdesivir, Liquid Medical Oxygen, Oximeter

Web Admin

Web Admin

5 Dariya News

London , 03 Jul 2022

Eight out of 10 antibody therapy available for treatment of Covid-19 patients do not inhibit the new and emerging sub-variants of Omicron such as BA.2.12.1, BA.4, and BA.5, according to a study published in The Lancet Infectious Diseases.

A team of researchers, including those from the German Primate Center (DPZ)-Leibniz Institute for Primate Research in Germany, studied 10 therapeutic antibodies - Sotrovimab by GlaxoSmithKline; Tixagevimab and Cilgavimab (packaged in Evusheld) by AstraZeneca; Bebtelovimab and cocktail Bamlanivimab and Etesevimab by Eli Lilly; Casirivimab-Imdevimab by Regeneron; Regdanvimab by Celltrion, and S2H97.

The findings showed that only two were able to at least partially inhibit BA.2.12.1, BA.4, and BA.5 and that only one antibody, Bebtelovimab, efficiently blocked infection by all Omicron sub-variants.

Furthermore, the study shows that the BA.2.12.1 and especially BA.4 and BA.5 are inhibited worse than their predecessors BA.1 and BA.2 by antibodies generated after vaccination or inoculation followed by infection.

It is because the BA.2.12.1, BA.4, and BA.5 are immune escape variants. A pass-through infection with "old" Omicron sub-variants confers only limited protection against infection with "new" sub-variants, the researchers explained.

"These results confirm a trend that we have already seen in previous studies: Omicron sub-variants are not appreciably inhibited by most therapeutic antibodies and the few antibodies that inhibit frequently do so in a subvariant-specific fashion. 

Therefore, it is important to develop new antibodies in order to be prepared for future sub-variants," said Prerna Arora, first author from the German Primate Center.

Antibodies from unvaccinated individuals that were infected with BA.1 or BA.2 in spring 2022 neutralised BA.2.12.1 with similar efficiency but were much less potent against BA.4 and BA.5. 

Therefore, it is likely that a previous BA.1 or BA.2 infection provides little protection against a subsequent infection with BA.4 or BA.5.Antibodies induced by three immunisations with the mRNA vaccine of BioNTech/Pfizer blocked all Omicron sub-variants. 

However, inhibition was less efficient as compared to that measured for a virus that circulated early during the pandemic, and inhibition of BA.2.12.1, BA.4, and BA.5 was less efficient as compared to BA.1 and BA.2.A

Similar results were obtained for antibodies induced upon vaccination plus breakthrough infection. Although this so-called hybrid immunity conferred overall higher neutralising activity against all variants tested, inhibition of BA.2.12.1, BA.4 and BA.5 was significantly reduced.

 

Tags: Omicron Variant , Delta Plus Covid variant , Delta Covid-19 variant , Coronavirus , Health , Research , Study , Researchers , COVID 19 , Novel Coronavirus , Fight Against Corona , Covaxin , Covishield , Oxygen , SARS-CoV-2 , Sputnik V , Oxygen Plants , Pfizer , Astra Zeneca , Oxygen Concentrator , Remdesivir , Liquid Medical Oxygen , Oximeter

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2022 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD